Sectors
DAWN
Day One Biopharmaceuticals, Inc.
21.53
2 x 15.47
2 x 27.50
bid
ask
+
0.00
0.00%
09:30 AM
timesize
| Ytd | 131.01% | |
| 1y | 172.53% |
21.53
day range
21.53
5.63
52 week range
21.53
| Open | 21.53 | Prev Close | 21.53 | Low | 21.53 | High | 21.53 | Mkt Cap | 2.22B |
| Vol | 0.00 | Avg Vol | 4.01M | EPS | -1.04 | P/E | -20.70 | Forward P/E | -177.57 |
| Beta | -1.74 | Short Ratio | 2.79 | Inst. Own | 83.49% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-05 | 50-d Avg | 18.21 | 200-d Avg | 10.72 | 1yr Est | 21.50 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-05 | 2026-03 | -0.31 | -0.35 | -0.04 | -12.90% |
| 2026-02-24 | 2025-12 | -0.17 | -0.2 | -0.03 | -17.65% |
| 2025-11-04 | 2025-09 | -0.28 | -0.19 | 0.09 | 31.75% |
| 2025-08-05 | 2025-06 | -0.35 | -0.29 | 0.06 | 17.14% |
| 2025-05-06 | 2025-03 | -0.46 | -0.35 | 0.11 | 23.91% |
| 2025-02-25 | 2024-12 | -0.35 | -0.69 | -0.34 | -97.14% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-03-11 | JP Morgan | Downgrade | Overweight | Neutral |
| 2026-03-10 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| 2026-03-09 | Wedbush | Downgrade | Outperform | Neutral |
| 2026-03-06 | Jones Trading | Downgrade | Buy | Hold |
| 2026-03-06 | Needham | Downgrade | Buy | Hold |
| 2026-02-25 | Wedbush | Upgrade | Outperform | Outperform |
Profile
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, currently undergoing Phase II clinical trials for young patients experiencing recurrent or worsening low-grade glioma. Additionally, the company is advancing Pimasertib, an oral small molecule designed to inhibit mitogen-activated protein kinase kinases 1 and 2. Established in 2018, Day One Biopharmaceuticals, Inc. maintains its primary operations in South San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-16 | BENDER JEREMY | Chief Executive Officer | 1.80M | Sale |
| 2024-12-09 | BLACKMAN SAMUEL C | Officer | 2.03M | Sale |
| 2026-02-16 | DUBOW ADAM | General Counsel | 72.69K | Sale |
| 2026-02-16 | MERENDINO LAUREN | Officer | 60.16K | Sale |
| 2024-06-20 | RAMASASTRY SAIRA | Director | 40.49K | Sale |
| 2026-02-16 | VASCONCELLES MICHAEL | Officer | 4.40K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Blackrock Inc. | 8.84M | 190.27M | 8.55% |
| 2025-12-30 | Atlas Venture Life Science Advisors, LLC | 6.41M | 138.06M | 6.21% |
| 2025-12-30 | Vanguard Group Inc | 6.28M | 135.26M | 6.08% |
| 2025-12-30 | FMR, LLC | 5.72M | 123.09M | 5.53% |
| 2025-12-30 | Vestal Point Capital, LP | 5.20M | 111.96M | 5.03% |
| 2025-12-30 | State Street Corporation | 4.29M | 92.35M | 4.15% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.41M | 51.93M | 2.33% |
| 2026-02-27 | iShares Trust-iShares Russell 2000 ETF | 1.90M | 40.83M | 1.84% |
| 2026-03-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17M | 25.08M | 1.13% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 875.00K | 18.84M | 0.85% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 794.82K | 17.11M | 0.77% |
| 2026-02-27 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 772.70K | 16.64M | 0.75% |